Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 5NIH 4NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Plasma cell 2Myeloid 2Lymphoid 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Melanoma 1

Interventions

Interferon-alpha 6Radiosurgery 4Dacarbazine 4encorafenib 3binimetinib 3aldesleukin 3Radiotherapy 3Methotrexate 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Etoposide 3Cyclophosphamide 3Cisplatin 3Watchful Waiting 2Vincristine 2Vinblastine 2Temozolomide 2Polymerase Chain Reaction 2Nivolumab 2Ipilimumab 2Introns 2Interferon alpha-2 2Immunologic Techniques 2Flow Cytometry 2Carboplatin 2trametinib 1tebentafusp 1sulforaphane 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Dasatinib × Dermatologic × Clear all
NCT00700882 2023-07-03

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Eastern Cooperative Oncology Group

Phase 2 Completed
81 enrolled 9 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡